Adimmune Corporation (TWSE: 4142) announced today that its July revenue was NT$277.34 million, a record high for July since Adimmune went public. Fueled by the overseas orders of quadrivalent influenza vaccine and CDMO products as well as the sales of rapid test kits contributed by Enimmune, the subsidiary, the July revenue soared four-fold, higher than that of last year, NT$52.811 million. 

With new highs in June and July, the Company points out that despite the recent global turbulence in the stock market, Adimmune’s efforts in international market expansion, production line expansion, international certifications, and process optimization have established a solid foundation for operation. 

Adimmune, the key supplier of domestic influenza vaccine in Taiwan, is also committed to globalization. The Company is in line with international standards in terms of regulatory certification, manufacturing specification, and quality control system. With the upcoming peak season for domestic influenza vaccine shipment, Adimmune anticipates further growth in Q3-Q4 results.